Scholarlink

Purpose <p>Development of a circulating extracellular vesicle-based IDH mutant protein detection technology for diagnosis of IDH mutation status in glioma, enabling personalized resection strategies, precision medication, and disease dynamics monitoring in IDH-mutant glioma.</p> Methods <p>We developed a tumor-classification strategy that discriminates tumor types by detecting the IDH1.R132H mutant protein in plasma extracellular vesicles using a bead-assisted, flow-cytometry–based assay. We assessed the differential expression’s capacity to distinguish tumor grades, analyzed pre-operative and post-operative expression variations, and verified consistency with histopathological immunohistochemistry.</p> Results <p>The method demonstrated a diagnostic sensitivity of 76.2% (95%CI: 54.9%–89.4%) and a specificity of 86.7% (95%CI: 62.1%–96.3%) for IDH-mutant glioma. Further analysis revealed that the expression level of the IDH mutant protein in plasma EVs was significantly associated with tumor grade in IDH-mutant glioma (P &lt; 0.0001). Moreover, the expression level of the IDH mutant protein in plasma EVs significantly decreased in post-operative patients (P &lt; 0.01) and showed a high degree of consistency with the pathological immunohistochemical results at different tumor grades.</p> Conclusion <p>We propose a novel plasma extracellular-vesicle liquid biopsy with potential preoperative application in detecting IDH-mutant glioma, affording noninvasive, rapid, efficient, and low-cost assessment of IDH mutation status.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Detection of IDH1.R132H mutant protein in plasma extracellular vesicles and its application in preoperative noninvasive precision diagnosis of glioma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月28日

查看全文
  • Minghang Liu,
  • Kai Zhao,
  • Chenxuan Yang,
  • Guochen Sun,
  • Dongdong Wu,
  • Yanlian Yang,
  • Bainan Xu

摘要

Purpose

Development of a circulating extracellular vesicle-based IDH mutant protein detection technology for diagnosis of IDH mutation status in glioma, enabling personalized resection strategies, precision medication, and disease dynamics monitoring in IDH-mutant glioma.

Methods

We developed a tumor-classification strategy that discriminates tumor types by detecting the IDH1.R132H mutant protein in plasma extracellular vesicles using a bead-assisted, flow-cytometry–based assay. We assessed the differential expression’s capacity to distinguish tumor grades, analyzed pre-operative and post-operative expression variations, and verified consistency with histopathological immunohistochemistry.

Results

The method demonstrated a diagnostic sensitivity of 76.2% (95%CI: 54.9%–89.4%) and a specificity of 86.7% (95%CI: 62.1%–96.3%) for IDH-mutant glioma. Further analysis revealed that the expression level of the IDH mutant protein in plasma EVs was significantly associated with tumor grade in IDH-mutant glioma (P < 0.0001). Moreover, the expression level of the IDH mutant protein in plasma EVs significantly decreased in post-operative patients (P < 0.01) and showed a high degree of consistency with the pathological immunohistochemical results at different tumor grades.

Conclusion

We propose a novel plasma extracellular-vesicle liquid biopsy with potential preoperative application in detecting IDH-mutant glioma, affording noninvasive, rapid, efficient, and low-cost assessment of IDH mutation status.